New biosimilar aims to rival blockbuster eczema drug
NCT ID NCT07411755
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests whether a new drug called GS101 works like the approved eczema treatment Dupixent. Researchers will give a single shot to 294 healthy adults in China and compare how the drug moves through the body, its safety, and immune response. The goal is to see if GS101 could be a similar, possibly cheaper option for managing atopic dermatitis.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- GS101 injection (a biosimilar of Dupixent)
- What this could lead to
- If successful, this could provide a more affordable alternative to Dupixent for managing eczema symptoms.
- What could go wrong
- This is an early Phase 1 trial in healthy people, not patients. It only checks if the drug is similar, not if it works for eczema. Side effects or differences may still appear.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS (AD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Second Affiliated Hospital of Soochow University
RECRUITINGSuzhou, Jiangsu, 215004, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can ozonated oil soothe eczema in kids?
- Can a Skin-Repairing cream soothe eczema?
- Can a new antibody calm severe eczema?
- Microscopic skin scans may reveal how a new eczema drug reshapes the skin
- Menthol gloves may offer quick itch relief for eczema sufferers
- One pill may tame both itchy skin and stubborn liver disease